文献速递焦虑、强迫与应激相关障碍

正念减压与艾司西酞普兰治疗成人焦虑障碍的随机临床试验

Mindfulness-Based Stress Reduction vs Escitalopram for the Treatment of Adults With Anxiety Disorders: A Randomized Clinical Trial.
PubMed 文献 · JAMA Psychiatry · 2023-01-01

这项随机临床试验纳入276名美国成人焦虑障碍患者,比较8周正念减压(MBSR)与艾司西酞普兰的疗效。

要点

  • MBSR在改善焦虑严重度方面不劣于艾司西酞普兰。
  • 艾司西酞普兰组因不良事件脱落10例(8%),MBSR组无因不良事件脱落。
  • 艾司西酞普兰组至少1起研究相关不良事件发生率为78.6%,MBSR组为15.4%。

核心结论

  • 在成人焦虑障碍患者中,8周MBSR在降低CGI-S评分方面不劣于艾司西酞普兰。

研究设计与样本

  • 随机临床试验(TAME),非劣效性设计,预设非劣效界值-0.495分。
  • 276名来自美国3个城市学术医疗中心的成人焦虑障碍患者被招募,208名完成试验。
  • 参与者1:1随机分配至8周每周MBSR课程或艾司西酞普兰(10-20 mg灵活剂量)。
  • 结局评估由盲法临床访谈者在基线、第8周终点及第12和24周随访时进行。

主要发现

  • 主要非劣效性样本208例(MBSR组102例,艾司西酞普兰组106例),平均年龄33(13)岁,女性156例(75%)。
  • 终点时CGI-S评分平均降低:MBSR组1.35(1.06),艾司西酞普兰组1.43(1.17)。
  • 基于插补数据的意向性分析次要结果同样显示MBSR不劣于艾司西酞普兰。
  • 开始治疗后因不良事件脱落:艾司西酞普兰组10例(8%),MBSR组0例。

关键数值与推荐

  • 主要终点为临床总体印象严重度量表(CGI-S)评估的焦虑水平。
  • 预设非劣效界值为-0.495分。
  • 艾司西酞普兰剂量灵活范围为10至20 mg。

临床怎么用

  • 对于成人焦虑障碍,MBSR可作为艾司西酞普兰之外的一种非劣效治疗选择。
  • 艾司西酞普兰组不良事件发生率较高,MBSR组因不良事件脱落为零。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Anxiety disorders are common, highly distressing, and impairing conditions. Effective treatments exist, but many patients do not access or respond to them. Mindfulness-based interventions, such as mindfulness-based stress reduction (MBSR) are popular and can decrease anxiety, but it is unknown how they compare to standard first-line treatments. OBJECTIVE: To determine whether MBSR is noninferior to escitalopram, a commonly used first-line psychopharmacological treatment for anxiety disorders. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial (Treatments for Anxiety: Meditation and Escitalopram [TAME]) included a noninferiority design with a prespecified noninferiority margin. Patients were recruited between June 2018 and February 2020. The outcome assessments were performed by blinded clinical interviewer at baseline, week 8 end point, and follow-up visits at 12 and 24 weeks. Of 430 individuals assessed for inclusion, 276 adults with a diagnosed anxiety disorder from 3 urban academic medical centers in the US were recruited for the trial, and 208 completed the trial. INTERVENTIONS: Participants were 1:1 randomized to 8 weeks of the weekly MBSR course or the antidepressant escitalopram, flexibly dosed from 10 to 20 mg. MAIN OUTCOMES AND MEASURES: The primary outcome measure was anxiety levels as assessed with the Clinical Global Impression of Severity scale (CGI-S), with a predetermined noninferiority margin of -0.495 points. RESULTS: The primary noninferiority sample consisted of 208 patients (102 in MBSR and 106 in escitalopram), with a mean (SD) age of 33 (13) years; 156 participants (75%) were female; 32 participants (15%) were African American, 41 (20%) were Asian, 18 (9%) were Hispanic/Latino, 122 (59%) were White, and 13 (6%) were of another race or ethnicity (including Native American or Alaska Native, more than one race, or other, consolidated owing to low numbers). Baseline mean (SD) CGI-S score was 4.44 (0.79) for the MBSR group and 4.51 (0.78) for the escitalopram group in the per-protocol sample and 4.49 (0.77) vs 4.54 (0.83), respectively, in the randomized sample. At end point, the mean (SD) CGI-S score was reduced by 1.35 (1.06) for MBSR and 1.43 (1.17) for escitalopram. The difference between groups was -0.07 (0.16; 95% CI, -0.38 to 0.23; P = .65), where the lower bound of the interval fell within the predefined noninferiority margin of -0.495, indicating noninferiority of MBSR compared with escitalopram. Secondary intent-to-treat analyses using imputed data also showed the noninferiority of MBSR compared with escitalopram based on the improvement in CGI-S score. Of patients who started treatment, 10 (8%) dropped out of the escitalopram group and none from the MBSR group due to adverse events. At least 1 study-related adverse event occurred for 110 participants randomized to escitalopram (78.6%) and 21 participants randomized to MBSR (15.4%). CONCLUSIONS AND RELEVANCE: The results from this randomized clinical trial comparing a standardized evidence-based mindfulness-based intervention with pharmacotherapy for the treatment of anxiety disorders found that MBSR was noninferior to escitalopram. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03522844.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Hoge EA, Bui E, Mete M, et al. Mindfulness-Based Stress Reduction vs Escitalopram for the Treatment of Adults With Anxiety Disorders: A Randomized Clinical Trial. JAMA Psychiatry. 2023. PMID: 36350591. doi:10.1001/jamapsychiatry.2022.3679

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。